hypoglycemia and glp-1 The impact of incretin-based therapies on counterregulatory responses to in diabetes mellitus: mechanisms and clinical implications image2.png
Description
The FDA has been vocal about its concerns in this category
BJU Int 123:877884
The final product, liraglutide (Victoza, Novo Nordisk), proved its effects in type 2 diabetes mellitus (T2DM) and was approved by the FDA in 2010 [19]
The increasing conversation around these medications-from news articles to personal success stories-has educated the public
Peptides 32 , 15811586 (2011)
